Back to top

GSK Targets Relapsed B-Cell Lymphoma With New Early-Stage Trial

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. The study titled “A Phase 1/2 Open-label, Multi-center Study to Evaluat...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

GSK PLC Sponsored ADR (GSK)